16. Survival and prognostic factors in recurrent/ metastatic squamous cell lung cancer patients after first-line paclitaxel - carboplatin chemotherapy
Main Article Content
Abstract
This study aimed to evaluate survival outcomes and analyze prognostic factors in 65 patients recurrent/ metastatic squamous cell lung cancer and received first-line paclitaxel - carboplatin chemotherapy at National Cancer Hospital from 01/2017 to 05/2022. This was retrospective study conducted from 01/2017 to 05/2022. The results showed that the average progression-free survival (PFS) was 4.89 ± 1.5 months and the median PFS was 4.6 months. The average overall survival (OS) was 13.2 ± 1.1 months and the median OS was 11.2 months. The 1-year OS rate was 54.8%. Survival is significantly associated with the patient’s condition before treatment. Recurrent/metastatic squamous cell lung cancer typically has poor prognosis with low progression-free survival and overall survival.
Article Details
Keywords
Squamous cell lung cancer, recurrent/ metastatic stage, National Cancer Hospital, paclitaxel-carboplatin
References
2. Cheng T-YD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics. Journal of Thoracic Oncology. 2016;11:1653-1671. doi: 10.1016/j.jtho.2016.05.021.
3. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014;84:13-22. doi: 10.1016/j.lungcan.2014.01.009.
4. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA, Kim ES, Langer CJ, Natale RB, Novello S, et al. Current and emergent therapy options for advanced squamous cell lung cancer. Journal of Thoracic Oncology. 2018;13:165-183. doi: 10.1016/j.jtho.2017.11.111.
5. Soldera SV, Leighl NB. Update on the treatment of metastatic squamous non-small cell lung cancer in New Era of personalized medicine. Frontiers in Oncology. 2017;7.
6. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379:2040-2051. doi: 10.1056/NEJMoa1810865.
7. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, et al. Atezolizumab for first-line treatment of PD-L1 - selected patients with NSCLC. N Engl J Med. 2020;383:1328-1339. doi: 10.1056/NEJMoa1917346.
8. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus Chemotherapy for PD-L1 -positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823-1833. doi: 10.1056/NEJMoa1606774.
9. El-Shenshawy HM, Taema S, El-Zahaf E, El-Beshbeshi W, Sharaf Eldeen D, Fathy A. Advanced non-small cell lung cancer in elderly patients: The standard every 3-weeks versus weekly paclitaxel with carboplatin. Egyptian Journal of Chest Diseases and Tuberculosis. 2012;61:485-493. doi: 10.1016/j.ejcdt.2012.08.019.
10. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Annals of Oncology. 2002;13:1539-1549. doi: 10.1093/annonc/mdf332.
11. Thomas P, Castelnau O, Paillotin D, Léna H, Robinet G, Muir JF, Delaval P, Gouva S, Balmes P, Blanchon F, et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: A groupe français de pneumo-cancérologie study. J Clin Oncol. 2001;19:1320-1325. doi: 10.1200/JCO.2001.19.5.1320.
12. Abbasi S, Badheeb A. Prognostic factors in advanced non-small-cell lung cancer patients: Patient characteristics and type of chemotherapy. Lung Cancer Int. 2011;2011:152125. doi: 10.4061/2011/152125.